# OnCo record pik3ca (target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/targets/pik3ca/>
  a schema:BioChemEntity ;
  onco:kind "target" ;
  schema:identifier "pik3ca" ;
  schema:name "PIK3CA / PI3K-alpha"@en ;
  schema:description "PIK3CA is the most commonly mutated gene in hormone-driven breast cancer. Drugs against it work, but hitting it cleanly without raising blood sugar took years."@en ;
  schema:url <https://onco.cc/targets/pik3ca/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/P110α>, <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8975>, <https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000121879>, <https://www.uniprot.org/uniprotkb/P42336/entry>, <https://www.ncbi.nlm.nih.gov/gene/5290> ;
  owl:sameAs <http://www.wikidata.org/entity/Q14887700> ;
  schema:citation <https://en.wikipedia.org/wiki/P110α> ;
  onco:tag "driver", "kinase" ;
  schema:alternateName "PIK3CA" ;
  onco:targetClass "kinase" ;
  onco:firstDescribed "1994"^^xsd:gYear ;
  onco:related <https://onco.cc/biomarkers/pik3ca-hotspot-mutation/> ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/prostate/> ;
  onco:technologies <https://onco.cc/technologies/pi3k-akt-mtor-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/therascreen-cdx/>, <https://onco.cc/drugs/tersolisib/>, <https://onco.cc/drugs/zovegalisib/>, <https://onco.cc/drugs/serabelisib/> ;
  onco:companies <https://onco.cc/companies/bridgebio-oncology-therapeutics/>, <https://onco.cc/companies/cogent-biosciences/>, <https://onco.cc/companies/relay-therapeutics/>, <https://onco.cc/companies/scorpion-therapeutics/> ;
  onco:pathways <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/breast-cancer-signalling/>, <https://onco.cc/pathways/chemical-carcinogenesis-receptor-activation/>, <https://onco.cc/pathways/colorectal-cancer-signalling/>, <https://onco.cc/pathways/endometrial-cancer-signalling/>, <https://onco.cc/pathways/gastric-cancer-signalling/>, <https://onco.cc/pathways/glioma-signalling/>, <https://onco.cc/pathways/pancreatic-cancer-signalling/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-tcga-breast-molecular-portraits-nature-2012/>, <https://onco.cc/key-papers/paper-bareche-tnbc-multiomic-heterogeneity-ann-oncol-2018/>, <https://onco.cc/key-papers/paper-jiang-fuscc-tnbc-landscape-cancer-cell-2019/>, <https://onco.cc/key-papers/paper-narayan-gallbladder-regional-mutations-cancer-2019/>, <https://onco.cc/key-papers/paper-giraldo-gallbladder-msk-impact-ccr-2022/>, <https://onco.cc/key-papers/paper-kris-lung-cancer-mutation-consortium-jama-2014/>, <https://onco.cc/key-papers/paper-tcga-lung-squamous-nature-2012/>, <https://onco.cc/key-papers/paper-tcga-molecular-taxonomy-primary-prostate-cell-2015/>, <https://onco.cc/key-papers/paper-carver-pi3k-ar-reciprocal-feedback-prostate-cancer-cell-2011/> .